Division of Gastric Surgery, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Shizuoka, 411-8777, Japan.
Department of Surgery, Osaka General Medical Center, Osaka, Japan.
Gastric Cancer. 2021 Jan;24(1):224-231. doi: 10.1007/s10120-020-01114-z. Epub 2020 Aug 13.
We had previously reported that surgical palliation could maintain quality of life (QOL) while improving solid food intake among patients with malignant gastric outlet obstruction (GOO) caused by advanced gastric cancer. The present study aimed to perform a survival analysis according to the patients' QOL to elucidate its impact on survival.
Patients with GOO who underwent either palliative gastrectomy or gastrojejunostomy were included in this study. A validated QOL instrument (EQ-5D) was used to assess QOL at baseline and 2 weeks, 1 month, and 3 months following surgical palliation. Postoperative improvement in oral intake was also evaluated using the GOO scoring system (GOOSS). Thereafter, univariate and multivariate survival analyses were performed to determine independent prognostic factors.
The median survival time of the 104 patients included herein was 11.30 months. Patients who received postoperative chemotherapy, PS 0/1, baseline EQ-5D ≥ 0.75, improved or stable EQ-5D, and improved oral intake expressed as GOOSS = 3 had significantly better survival. Multivariate analysis identified postoperative chemotherapy, a better baseline PS, a better baseline EQ5D, improved or stable EQ5D scores, and improved oral intake 3 months after surgical palliation as independent prognostic factors.
Apart from preoperative PS and postoperative chemotherapy, the present study identified better baseline QOL, improvement in postoperative QOL, and improvement in oral intake as prognostic factors among patients who underwent palliative surgery for advanced gastric cancer with GOO.
我们之前曾报道过,手术姑息治疗可以维持生活质量(QOL),同时改善晚期胃癌引起的恶性胃出口梗阻(GOO)患者的固体食物摄入。本研究旨在根据患者的 QOL 进行生存分析,以阐明其对生存的影响。
本研究纳入了接受姑息性胃切除术或胃空肠吻合术的 GOO 患者。使用经过验证的 QOL 工具(EQ-5D)在手术姑息治疗前、治疗后 2 周、1 个月和 3 个月评估 QOL。还使用 GOO 评分系统(GOOSS)评估术后口腔摄入的改善情况。然后,进行单因素和多因素生存分析,以确定独立的预后因素。
本研究纳入的 104 例患者的中位生存时间为 11.30 个月。接受术后化疗、PS 0/1、基线 EQ-5D≥0.75、EQ-5D 改善或稳定以及口服摄入量改善(GOOSS=3)的患者具有显著更好的生存。多因素分析确定术后化疗、更好的基线 PS、更好的基线 EQ5D、改善或稳定的 EQ5D 评分以及手术姑息治疗 3 个月后口服摄入量改善是独立的预后因素。
除了术前 PS 和术后化疗外,本研究还确定了更好的基线 QOL、术后 QOL 的改善以及口服摄入量的改善是接受姑息性手术治疗 GOO 的晚期胃癌患者的预后因素。